GlassScriptPhysician profile
Charisse C Hook
NPI 1891822292
$5,120.73
in general payments reported to CMS, 2019-2025
19 companies · $1,702 in 2025
The $1,702 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $303 · 2023: $1,494 · 2024: $1,621 · 2025: $1,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,817.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,240.82 | 2022-2025 | |
| Alkermes, INC. | $724.27 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $592.54 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $561.85 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $533.32 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Lundbeck LLC | $337.08 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $319.02 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $250.26 | 2023-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $132.47 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $89.15 | 2022-2024 | Trintellix |
| Corium, LLC | $76.70 | 2023-2025 | Azstarys |
| Validus Pharmaceuticals LLC | $58.59 | 2025 | Raldesy, Equetro |
| Vanda Pharmaceuticals INC. | $45.95 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $39.37 | 2024-2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $34.69 | 2023 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $26.22 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.76 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.66 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $17.01 | 2025 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charisse Hook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.